Crescent Biopharma to Present at March Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
According to Crescent Biopharma, each presentation will be webcast live and replays will be available via the Investors section of the company's website for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CBIO slipped 0.77% while only one peer (CRBU) appeared on momentum scans, up 1.1099999770522118% with no same-day news; other peers showed mixed moves, pointing to stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | IND clearances | Positive | +0.3% | IND clearances for CR-001 and CR-003 oncology programs with ASCEND plan. |
| Jan 30 | Inducement grants | Neutral | +2.4% | Employee inducement equity option awards under 2025 plan with 10-year term. |
| Feb 05 | Conference appearance | Neutral | -3.1% | Guggenheim biotech summit fireside chat with webcast and 90-day replay. |
| Feb 18 | Clinical trial start | Positive | +4.2% | First patient dosed in ASCEND Phase 1/2 CR-001 trial for solid tumors. |
| Feb 19 | Inducement awards | Positive | +14.2% | Inducement option grants totaling 24,600 shares to non-executive employees. |
Recent news, particularly clinical progress and corporate actions, has generally seen positive price alignment, including strong upside on routine items like inducement awards.
Over the last few months, Crescent Biopharma has reported multiple milestones. IND clearances for CR-001 and CR-003 on Jan 5, 2026 saw a modest 0.27% gain, while inducement option grants on Jan 30, 2026 coincided with a 2.40% rise. A Guggenheim summit presentation on Feb 5, 2026 preceded a 3.09% decline. Launch of the ASCEND Phase 1/2 trial on Feb 18, 2026 brought a 4.18% increase, and further inducement awards on Feb 19, 2026 saw a strong 14.15% move, underscoring sensitivity to corporate updates.
Market Pulse Summary
This announcement highlights Crescent Biopharma’s continued visibility efforts via fireside chats at TD Cowen’s health care conference on March 2, 2026 and Leerink’s global healthcare conference on March 11, 2026, each with webcasts and 90-day replays. In recent months, the company advanced key programs, including IND clearances and the ASCEND Phase 1/2 trial start, which previously aligned with positive price reactions. Investors may watch upcoming clinical readouts, additional regulatory filings, and future融资 steps disclosed in SEC documents.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
- TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.
- Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
FAQ
When will Crescent Biopharma (CBIO) present at the TD Cowen 46th Annual Health Care Conference?
What time is Crescent Biopharma (CBIO) scheduled for the Leerink Partners 2026 Global Healthcare Conference?
Where can investors watch the Crescent Biopharma (CBIO) March 2026 conference presentations live?
How long will Crescent Biopharma (CBIO) make replays of the March 2026 investor presentations available?
Will Crescent Biopharma (CBIO) cover clinical updates during the March 2026 investor conference presentations?
